Intelligence · Clinical Development
Pipeline search results
Programs matching “pemetrexed” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 25 pipeline programs matching "pemetrexed" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
CANAKINUMAB, PEMETREXED
Novartis Pharmaceuticals
Non-small cell lung cancer
1 trial -
Pemetrexed
Eli Lilly and Company
Non-Small Cell Lung Cancer
2 trials -
Pemetrexed
Boehringer Ingelheim
Carcinoma, Non-Small-Cell Lung
1 trial -
Pemetrexed
Regeneron UK Limited
Carcinoma，Non-Small-Cell Lung
1 trial -
Pemetrexed 500mg/m2 iv
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
Pemetrexed 500mg/m2 iv
Hospital Authority, Hong Kong
NSCLC
1 trial -
UC-IMM-2101
Ningbo Cancer Hospital
Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).
1 trial -
pemetrexed
Eli Lilly and Company
Head and Neck Neoplasms
1 trial -
Anlotinib plus Pemetrexed
Henan Provincial People's Hospital
Non-squamous Cell Non-Small Cell Lung Cancer
1 trial -
Cyclophosphamide+Pemetrexed+5-Fluorouracil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Thyroid Gland Carcinoma
1 trial -
HLX07+carboplatin+pemetrexed
Shanghai Henlius Biotech
HLX07, nsqNSCLC, High EGFR Expression
1 trial -
Intraventricular Pemetrexed
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Leptomeningeal Metastasis
1 trial -
Pemetrexed
Mereo BioPharma Group plc
Nonsquamous Nonsmall Cell Neoplasm of Lung
1 trial -
Pemetrexed
Samsung Bioepis NL B.V.
Colorectal Cancer
1 trial -
Pemetrexed
The First People's Hospital of Lianyungang
Colorectal Neoplasms
1 trial -
Pemetrexed
The First People's Hospital of Lianyungang
Leptomeningeal Metastasis
2 trials -
Pemetrexed (1)
The First People's Hospital of Lianyungang
Leptomeningeal Metastases
1 trial -
Pemetrexed Ever Pharma /ml concentrato per so...
Fondazione Telethon ETS
Non-small cell lung cancer (NSCLC)
1 trial -
Pemetrexed and Reolysin (and safety run-in)
ONCOLYTICS BIOTECH INC
Non Small Cell Lung Cancer
1 trial -
cis Platinum/Carboplatin, Pemetrexed Disodium
Shanghai University of Traditional Chinese Medicine
Chemotherapy, Adjuvant
1 trial -
pemetrexed
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Brain Metastases
1 trial -
pemetrexed
United Therapeutics Europe Ltd
Lung Cancer
1 trial -
INSIGHT
The George Institute
Histologically confirmed locally advanced or metastatic solid tumor (Strata A, B, D): Specification for Stratum C: Only patients with NSCLC adenocarcinomas, (squamous or adenosquamous not permitted) who are scheduled to receive platin + pembrolizumab + pemetrexed standard treatment (only for Stratum C) Specification for Stratum E: Including only metastatic or irresectable locally advanced urothelial carcinomas (only for Stratum E)
1 trial -
Pemetrexed
The First People's Hospital of Lianyungang
Leptomeningeal Metastases
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.